LONDON – 26 MAY 2026
This ticket gains you access to the 2026 Business of Cannabis Awards party at Rivington Street (8pm).
LONDON – 26-27 MAY 2026
Includes all Standard benefits plus premium upgrades: VIP lounge access, priority seating, concierge assistance, lunch on both days.
Complimentary access to BofC Awards Party.
LONDON – 26-27 MAY 2026
General Release
VIP Experience
BoC Awards
Working with Prohibition Partners for Cannabis Europa has been an absolute pleasure. Their dedication, exceptional professionalism, and collaborative spirit have made a meaningful difference, and we sincerely value their support.
We were truly honoured to sponsor the VIP Lounge and be part of an event that continues to set the standard for meaningful dialogue and progress in the medical cannabis industry. We left feeling excited and optimistic about the future.
We’re reimagining the VIP experience at Cannabis Europa London this year — a forum created exclusively for senior stakeholders, policymakers and investors defining the European market.
VIP delegates will have access to a separate space with its own agenda, service team and communications, designed to sit alongside the main conference, but separate from the hustle and bustle of the busy conference floor.
Facilitating candid, off-record and in-depth dialogue.
Live updates & capital allocation strategies.
Pre-bookable booths to get deals done.
Ensuring seamless scheduling & efficient networking.
Plus closing drinks reception & VIP networking.
Plus post-event partner introductions delivered digitally.
Cannabis Europa brings together the brightest minds in cannabis policy, business, and investment. Over two days in London, you’ll engage with policymakers, investors, scientists, and entrepreneurs to explore opportunities in one of the world’s fastest-evolving markets.
Our speakers are global thought-leaders driving change in policy, research, and commerce. Hear their insights, challenge your thinking, and leave with actionable strategies.
From high-level policy debates to practical market strategies, Cannabis Europa London 2026 is designed to give you the knowledge and connections you need to lead.
The UK cannabis story in 2026 is still defined by a stubborn gap between policy and practice. Nearly eight years after medical cannabis was rescheduled, NHS access remains limited, while private clinics continue to grow and fill the void amid increasing patient demand. At the same time, policymakers are being forced to confront a wider set of questions around what an open, modern UK cannabis framework should actually look like. This session asks a simple question: is the UK finally ready to move from caution to action? This discussion will examine whether the UK can ever realise its obvious potential within the current framework and what would need to happen for it to do so.
For all the growth of legal medical cannabis markets, the international framework governing the plant remains rooted in a far more restrictive era. Under the 1961 Single Convention, cannabis is permitted for medical and scientific use, yet even after the UN's 2020 decision to remove it from Schedule IV, it remains in Schedule I, leaving countries to apply some of the strictest controls in global drug policy to a medicine that is now legally prescribed across multiple jurisdictions. That contradiction is becoming harder to ignore as more patients travel with prescribed cannabis only to face seizure, uncertainty or outright criminalisation at borders. This discussion asks whether incremental progress is enough, or whether meaningful patient access now demands a more ambitious, top-down rethink of cannabis in international law.
The Road Traffic Act in the UK criminalises driving over the specified blood limit for controlled drugs, including THC, but it also creates a statutory medical defence if the medicine was lawfully prescribed and taken according to directions. Patients taking their medicine in the workplace can also present a different, equally pertinent set of issues. This general uncertainty is compounded by a lack of operational clarity across public bodies. For example, the DVLA stated in response to an FOI request that it holds no CBPM-specific medical guidance and is "not required to investigate the effects of medication on safe driving." Meanwhile, a Department for Transport parliamentary answer directs patients back to prescriber advice and the general drug-driving regime. This session asks what "policy in practice" should look like when the law recognises a medical defence, but systems and institutions still struggle to apply it consistently — from roadside stops to HR decisions.
In December 2025, President Trump signed an executive order directing federal agencies to move ahead with loosening marijuana regulations, putting the issue back at the centre of the national political conversation. This fireside discussion will explore what rescheduling would, and would not, actually change. How much depends on the White House, how much sits with the DEA and the courts, and what does continued uncertainty mean for investors, operators and international stakeholders watching the U.S. from abroad? As federal reform remains unfinished, this session will examine whether rescheduling is a genuine turning point or simply another chapter in a stop-start reform story.
Europe's patchwork of pilot programmes offers a unique opportunity to build evidence-based policies. Switzerland's trials cap purchases and monitor consumption patterns; early results show high participant satisfaction and minimal public-order issues. The Netherlands' experiment includes independent research on public health, crime and nuisance. This panel will examine how regulators can harness data to design effective laws, from setting THC limits to determining distribution models. Researchers, policymakers and industry analysts will discuss data collection challenges, the role of academic partnerships, and how to translate pilot findings into scalable frameworks. The conversation will also highlight gaps in clinical evidence and the need for European clinical trials.
After years of hype, Europe's cannabis market is finally finding its financial footing. The region's legal medical market could surpass €1.5 billion, and the UK's market alone is valued at €300 million. But institutional capital demands governance, tax compliance and reliable financial reporting. In this session, panellists from investment funds, accounting firms and major operators will discuss what investors look for, how valuations are evolving, and which jurisdictions are most attractive. The conversation will explore debt financing, venture capital, IPO prospects, and the growing importance of ESG metrics.
The UK cannabis market may still be tightly constrained, but that does not mean the window for entrepreneurship has closed. In many ways, the opposite is true. While broader reform remains uncertain, a growing medical market, an evolving CBD framework, renewed focus on domestic innovation and persistent gaps across supply chains are creating space for a new generation of startups to enter early and build strategically. This session explores where the real opportunities lie for founders, investors and operators looking to establish themselves in the UK today. From cultivation and product development to clinic infrastructure and patient services, panellists will examine which parts of the market remain underbuilt, where demand is outpacing delivery, and how businesses can create value under the current rules.
After decades of federal inaction, the United States is beginning to construct a coherent regulatory framework for cannabis, and the shape it is taking has implications on both sides of the Atlantic. The proposed rescheduling of cannabis to Schedule III would formally recognise its medical value under federal law for the first time, opening new research pathways and restructuring the tax environment for operators. Separately, recent legislative changes to the federal definition of hemp signal a broader move toward bringing the entire cannabinoid category under meaningful federal oversight. This session asks what that process looks like from a European perspective — and as both markets mature, what genuine regulatory convergence, or divergence, means for businesses operating across borders.
Offering European cannabis market insights through a data-driven presentation featuring the latest findings from Prohibition Partners. Attendees will explore market size, regulatory developments, investment trends, and emerging opportunities across medical and adult-use sectors. The session connects comprehensive market intelligence with actionable insights, helping investors, operators, and industry professionals navigate Europe's rapidly evolving cannabis ecosystem.
Connecting scientific data with real-world cultivation. A research-driven session exploring how growth conditions, plant genetics, and cultivation techniques influence cannabinoid profiles, potency, and consistency. The session connects scientific data with practical applications, offering actionable insights for growers, clinicians, and researchers seeking to optimise outcomes.
Shining a light on emerging findings on CB1 receptor biomarkers and the endocannabinoid system. Offering expert insights into tolerance, implications for medical cannabis use, and the latest scientific research driving treatment strategies. The session encourages discussion and questions, connecting patients, clinicians, and researchers to bridge scientific discovery with real-world application.
The Medical Cannabis Consumption Device Forum is an expert-led, open-discussion session designed to educate medical cannabis patients on vaporisation technologies. Participants can explore different device types, compare their pros and cons, and gain practical guidance on use, maintenance, and safety. The forum encourages peer-led conversation and shared patient experiences, while also serving as an informal feedback platform for leading vape manufacturers — helping bridge real-world patient insight with industry innovation.
Telemedicine has fuelled Europe's medical cannabis boom, especially in Germany, where imports surged 19% in Q3 2025. Yet the Bundesrat and health authorities are moving to curb online prescribing and mail-order sales, following Poland's restrictive example. This session explores the implications of telehealth crackdowns for patients, clinics and investors. Experts will discuss compliance strategies, EU cross-border prescription rules, the role of in-person consultations and potential technology solutions for verifying prescriptions while preserving patient access. The conversation will also address how restrictions may shift demand to illicit or unregulated channels and what advocacy efforts are needed to maintain equitable access.
Europe's maturing medical markets are facing serious price compression. German bulk prices have dropped significantly while EU-GMP products still command a premium. Switzerland and the UK report similar downward pressure, and oversupply looms as cultivation capacity ramps up. This panel will discuss strategies for managing slim margins: innovative cost reduction, product differentiation, branded premium segments, and long-term offtake agreements. Panellists will examine how pricing volatility impacts valuations and capital raises, and debate whether consolidation or supply-chain rationalisation will restore balance to Europe's cannabis economy.
As women increasingly turn to cannabis to manage under-treated health conditions — from endometriosis and chronic pelvic pain to sexual dysfunction and menopause symptoms — they are driving significant shifts across the sector, from policy debates and research priorities to product innovation and patient access. Women face a different set of challenges when accessing medical cannabis, from stigma and systemic barriers to a lack of products that meet their needs. The market has seen little innovation beyond high-THC and inhalation delivery methods, despite many women expressing a preference for formats that are easier to integrate into everyday life. This panel will explore the intersection of women's health and medical cannabis, examining persistent gaps in women's healthcare and the potential role that cannabis-based treatments could play in filling these.
For years, flower has been the defining product of Europe's medical cannabis market, valued by patients for its familiarity, fast onset and breadth of use. But as new national frameworks emerge, a different model is taking shape. Spain's incoming system is centred on standardised oral preparations made in hospital pharmacies, France is progressing with a tightly controlled medical model that also excludes raw flower, and across Europe regulators are showing growing preference for formats that look, dose and behave more like conventional medicines. This panel asks whether Europe is genuinely moving away from flower, or simply building newer markets in a more politically cautious and clinically conventional way. It will examine whether extracts, capsules, pastilles and medical devices are better suited to winning clinician trust and regulatory acceptance, and whether that comes at the expense of patient choice.
Dr Hana Al Hallaj explores how innovation in cannabis is shaped not simply by legalisation, but by the structure and clarity of regulation. Drawing on cross-country data, patent trends, and real-world market dynamics, she examines how different regulatory models influence product development — from basic flower to advanced pharmaceutical formulations. The session highlights where innovation truly emerges, how capital follows regulatory certainty, and what this means for investors and operators navigating global markets.
Join the leading voices in cannabis policy and business. We’re proud to partner with organisations at the forefront of cannabis innovation, investment, and regulation.
We’re proud to partner with organisations at the forefront of cannabis innovation, investment, and regulation.
Cannabis Europa brings together the brightest minds in cannabis policy, business, and investment. Over two days in London, you’ll engage with policymakers, investors, scientists, and entrepreneurs to explore opportunities in one of the world’s fastest-evolving markets.
A curated selection of hotels close to The Barbican, available at preferential delegate rates. Availability and pricing are updated in real time — book early to secure your preferred option.
Rates are applied automatically when booking through this portal. No discount codes required.
The debate around cannabis reform in the United Kingdom has grown more structured, more evidence-based, and more commercially significant in recent years. Yet legislative change at the national level remains absent. Understanding why — and what the realistic trajectory looks like — matters as much to investors and business leaders as it does to policymakers […]
The European cannabis landscape is entering a high-growth phase, marked by the arrival of seasoned entrepreneurs and major institutional shifts. As Cannabis Europa London 2026 approaches, the first wave of speakers has been announced, highlighting a diverse intersection of pharmaceutical innovation, global policy, and venture capital. Martin Dickie MBE & Waterside Pharmaceuticals A major highlight […]
With dedicated sessions on M&A, investment, pricing strategy and market access, Cannabis Europa London 2026 is the room where Europe’s cannabis industry does business. There are cannabis conferences, and then there are the events where decisions actually get made. Cannabis Europa London has established itself as the latter—a curated gathering of the operators, investors, policymakers […]
Germany and Poland are tightening the rules on online prescribing. The ripple effects will reshape medical cannabis access across the continent. Telemedicine didn’t just support the growth of European medical cannabis—it turbocharged it. Online consultations and e-prescriptions lowered barriers for patients, expanded clinic reach beyond urban centres, and drove a surge in imports across the […]
Subscribe to receive the latest updates on cannabis regulation, investment, and innovation in Europe.
